State of Alaska Department of Revenue grew its stake in shares of Colfax Co. (NYSE:CFX) by 14.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,142 shares of the industrial products company’s stock after buying an additional 2,203 shares during the quarter. State of Alaska Department of Revenue’s holdings in Colfax were worth $537,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Bessemer Group Inc. bought a new stake in shares of Colfax during the 2nd quarter worth about $1,098,000. Marshall Wace North America L.P. acquired a new position in shares of Colfax in the 2nd quarter worth approximately $1,035,000. Neuberger Berman Group LLC grew its stake in shares of Colfax by 7.7% in the 2nd quarter. Neuberger Berman Group LLC now owns 22,264 shares of the industrial products company’s stock worth $621,000 after purchasing an additional 1,583 shares during the last quarter. Natixis Advisors L.P. acquired a new position in shares of Colfax in the 2nd quarter worth approximately $2,555,000. Finally, California Public Employees Retirement System grew its stake in shares of Colfax by 7.3% in the 2nd quarter. California Public Employees Retirement System now owns 222,930 shares of the industrial products company’s stock worth $6,220,000 after purchasing an additional 15,231 shares during the last quarter.

Shares of CFX opened at $31.69 on Friday. The company’s 50 day moving average price is $32.48 and its 200 day moving average price is $28.80. Colfax Co. has a 52 week low of $12.23 and a 52 week high of $39.30. The company has a market capitalization of $3.75 billion, a PE ratio of -452.71, a PEG ratio of 4.20 and a beta of 1.89. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.89 and a current ratio of 1.62.

Colfax (NYSE:CFX) last announced its quarterly earnings data on Thursday, August 6th. The industrial products company reported $0.09 EPS for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.03. Colfax had a negative net margin of 0.33% and a positive return on equity of 6.54%. The firm had revenue of $620.40 million for the quarter, compared to the consensus estimate of $581.26 million. During the same period in the previous year, the firm posted $0.64 earnings per share. The firm’s revenue was down 31.7% on a year-over-year basis. On average, equities analysts forecast that Colfax Co. will post 1.37 earnings per share for the current fiscal year.

Several brokerages have recently issued reports on CFX. Bank of America lifted their price objective on shares of Colfax from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, September 16th. UBS Group began coverage on shares of Colfax in a research note on Tuesday, September 15th. They issued a “neutral” rating and a $36.00 price objective on the stock. ValuEngine raised shares of Colfax from a “sell” rating to a “hold” rating in a research note on Friday, August 7th. KeyCorp lifted their price objective on shares of Colfax from $33.00 to $36.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Barclays lifted their target price on shares of Colfax from $31.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 7th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the stock. Colfax currently has a consensus rating of “Hold” and a consensus target price of $30.08.

In other Colfax news, CEO Matthew L. Trerotola sold 19,481 shares of Colfax stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $30.83, for a total value of $600,599.23. Following the completion of the sale, the chief executive officer now directly owns 223,006 shares in the company, valued at $6,875,274.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jason Maclean sold 2,491 shares of Colfax stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $35.32, for a total transaction of $87,982.12. Following the completion of the sale, the senior vice president now owns 8,815 shares of the company’s stock, valued at $311,345.80. The disclosure for this sale can be found here. Insiders own 12.00% of the company’s stock.

Colfax Company Profile

Colfax Corporation operates as a diversified technology company worldwide. The company operates through two segments, Medical Technology and Fabrication Technology. The Medical Technology segment offers orthopedic solutions, including orthopedic devices and braces, reconstructive and surgical implants, footwear, bone growth stimulators, and software and services spanning the full continuum of patient care, as well as injury prevention, rehabilitation, pain management, and physical therapy under the Aircast, Chattanooga, CMF, Compex, DonJoy, ProCare, DJO Surgical, Dr.

Read More: What is a death cross?

Institutional Ownership by Quarter for Colfax (NYSE:CFX)

Receive News & Ratings for Colfax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colfax and related companies with MarketBeat.com's FREE daily email newsletter.